MedTrace Logo

Perioperative Propranolol During Prostatectomy to Decrease Cancer Recurrence

NCT05679193 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-05-29

No results posted yet for this study

Summary

The purpose of this study is to assess the feasibility of conducting a larger randomized controlled trial to assess the efficacy of perioperative propranolol capsules compared with placebo capsules in decreasing recurrence of prostate cancer (PCa) after robotic assisted laparoscopic prostatectomy (RALP) in participants with intermediate to high-risk for prostate cancer recurrence.

Conditions

Interventions

DRUG

Propranolol

Propranolol capsules 20mg taken orally. Day: 1-3: 20mg twice daily Day: 4-19 (25 , In cases of delayed RALP an extension of up to 6 days is allowed.in cases of delayed surgery). 2x 20mg twice daily Day 20-22 20mg twice daily

Sponsors & Collaborators

  • Ivar, Ragna og Morten Holes legat til fremme av kreftforskningen i Norge

    collaborator UNKNOWN

  • Fondsstiftelsen ved Oslo Universitetssykehus

    collaborator UNKNOWN

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Shivanthe Sivanesan, MD · Oslo University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-02
Primary Completion
2023-11-28
Completion
2024-01-27

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05679193 on ClinicalTrials.gov